TNFRSF18 and Hyperglycemia: As shown in figure 1A, anti-GITR-treated mice showed a significant and quite impressive acceleration of overt diabetes onset; mice receiving the higher anti-GITR dose developed hyperglycemia and glycosuria by 6–8 weeks of age that is 5–7 weeks before disease onset in control NOD females.